Cryptococcus neoformans

Last updated

Cryptococcus neoformans
Cryptococcus neoformans using a light India ink staining preparation PHIL 3771 lores.jpg
Yeast state of Cryptococcus neoformans
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Eukaryota
Kingdom: Fungi
Division: Basidiomycota
Class: Tremellomycetes
Order: Tremellales
Family: Cryptococcaceae
Genus: Cryptococcus
Species:
C. neoformans
Binomial name
Cryptococcus neoformans
(San Felice) Vuill. (1901)
Synonyms

Saccharomyces neoformansSan Felice (1895)
Filobasidiella neoformansKwon-Chung (1975)

Contents

Cryptococcus neoformans is an encapsulated basidiomycetous yeast [1] belonging to the class Tremellomycetes and an obligate aerobe [2] that can live in both plants and animals. Its teleomorph is a filamentous fungus, formerly referred to Filobasidiella neoformans. In its yeast state, it is often found in bird excrement. It has remarkable genomic plasticity and genetic variability between its strains, making treatment of the disease it causes difficult. [3] Cryptococcus neoformans causes disease primarily in immunocompromised hosts, such as HIV or cancer patients. [1] [4] [5] In addition it has been shown to cause disease in apparently immunocompetent hosts, especially in developed countries.

Classification

Cryptococcus neoformans has undergone numerous nomenclature revisions since its first description in 1895. It formerly contained two varieties: C. neoformans var. neoformans and C. neoformans var. grubii. A third variety, C. neoformans var. gattii, was later defined as a distinct species, Cryptococcus gattii . The most recent classification system divides these varieties into seven species. [6] C. neoformans refers to C. neoformans var. grubii. A new species name, Cryptococcus deneoformans, is used for the former C. neoformans var. neoformans. C. gattii is divided into five species.[ citation needed ]

The teleomorph was first described in 1975 by K.J. Kwon-Chung, who obtained cultures of Filobasidiella neoformans by crossing strains of the yeast C. neoformans. She was able to observe basidia similar to those of the genus Filobasidium , hence the name Filobasidiella for the new genus. [7] Following changes to the International Code of Nomenclature for algae, fungi, and plants, the practice of giving different names to teleomorph and anamorph forms of the same fungus was discontinued, meaning that Filobasidiella neoformans became a synonym of the earlier name Cryptococcus neoformans.[ citation needed ]

Characteristics

C. neoformans stained by Gram stain Cryptococcus Gram film.jpg
C. neoformans stained by Gram stain

Cryptococcus neoformans typically grows as a yeast (unicellular) and replicates by budding. It makes hyphae during mating, and eventually creates basidiospores at the end of the hyphae before producing spores. Under host-relevant conditions, including low glucose, serum, 5% carbon dioxide, and low iron, among others, the cells produce a characteristic polysaccharide capsule. [8] The recognition of C. neoformans in Gram-stained smears of purulent exudates may be hampered by the presence of the large gelatinous capsule which apparently prevents definitive staining of the yeast-like cells. In such stained preparations, it may appear either as round cells with Gram-positive granular inclusions impressed upon a pale lavender cytoplasmic background or as Gram-negative lipoid bodies. [9] When grown as a yeast, C. neoformans has a prominent capsule composed mostly of polysaccharides. Under the microscope, the India ink stain is used for easy visualization of the capsule in cerebral spinal fluid. [10] The particles of ink pigment do not enter the capsule that surrounds the spherical yeast cell, resulting in a zone of clearance or "halo" around the cells. This allows for quick and easy identification of C. neoformans. Unusual morphological forms are rarely seen. [11] For identification in tissue, mucicarmine stain provides specific staining of polysaccharide cell wall in C. neoformans. Cryptococcal antigen from cerebrospinal fluid is thought to be the best test for diagnosis of cryptococcal meningitis in terms of sensitivity, though it might be unreliable in HIV-positive patients. [12]

The first genome sequence for a strain of C. neoformans (var. neoformans; now C. deneoformans) was published in 2005. [5]

Studies suggest that colonies of C. neoformans and related fungi growing within the ruins of the Chernobyl Nuclear Power Plant may be able to metabolize ionizing radiation. [13]

Pathology

Infection with C. neoformans is termed cryptococcosis. Most infections with C. neoformans occur in the lungs, as the fungus enters its host through the respiratory route. [14] However, fungal meningitis and encephalitis, especially as a secondary infection for AIDS patients, are often caused by C. neoformans, making it a particularly dangerous fungus. Infections with this fungus were thought to be rare in people with fully functioning immune systems, hence C. neoformans is often referred to as an opportunistic pathogen. [1] However, a study from 2024 done in Australia and New Zealand showed the vast majority of recorded infections to be in non-HIV patients. [5] The fungus is a facultative intracellular pathogen [15] that can utilize host phagocytes to spread within the body. [16] [17] C. neoformans was the first intracellular pathogen for which the non-lytic escape process termed vomocytosis was observed. [18] [19] It has been speculated that this ability to manipulate host cells results from environmental selective pressure by amoebae, a hypothesis first proposed by Arturo Casadevall under the term "accidental virulence". [20]

In human infection, C. neoformans is spread by inhalation of aerosolized basidiospores or dehydrated fungal cells, and can disseminate to the central nervous system, where it can cause meningoencephalitis. [21] In the lungs, C. neoformans cells are phagocytosed by alveolar macrophages. [22] Macrophages produce oxidative and nitrosative agents, creating a hostile environment, to kill invading pathogens. [23] However, some C. neoformans cells can survive intracellularly in macrophages because of the protective nature of the polysaccharide capsule as well as its ability to produce melanin. [22] [3] Intracellular survival appears to be one of the factors contributing to latency, disseminated disease, and resistance to eradication by antifungal agents. One mechanism by which C. neoformans survives the hostile intracellular environment of the macrophage involves upregulation of expression of genes involved in responses to oxidative stress. [22]

Traversal of the blood–brain barrier by C. neoformans plays a key role in meningitis pathogenesis. [24] However, precise mechanisms by which it passes the blood-brain barrier are still unknown; a 2014 study in rats suggested an important role of secreted serine proteases. [25] The metalloprotease Mpr1 has been demonstrated to be critical in blood-brain barrier penetration. [26]

Meiosis (sexual reproduction), another possible survival factor for intracellular C. neoformans

The vast majority of environmental and clinical isolates of C. neoformans are mating type alpha. Filaments of mating type alpha have haploid nuclei ordinarily, but these can undergo a process of diploidization (perhaps by endoduplication or stimulated nuclear fusion) to form diploid cells termed blastospores. The diploid nuclei of blastospores are able to undergo meiosis, including recombination, to form haploid basidiospores that can then be dispersed. [27] This process is referred to as monokaryotic fruiting. Required for this process is a gene designated dmc1, a conserved homologue of genes recA in bacteria, and rad51 in eukaryotes (see articles recA and rad51). Dmc1 mediates homologous chromosome pairing during meiosis and repair of double-strand breaks in DNA. [28] One benefit of meiosis in C. neoformans could be to promote DNA repair in the DNA-damaging environment caused by the oxidative and nitrosative agents produced in macrophages. [27] Thus, C. neoformans can undergo a meiotic process, monokaryotic fruiting, that may promote recombinational repair in the oxidative, DNA-damaging environment of the host macrophage, and this may contribute to its virulence.[ citation needed ]

Serious complications of human infection

Infection begins in the lungs, and from there the fungus can disseminate to the brain and other body parts via macrophages. An infection of the brain caused by C. neoformans is referred to as cryptococcal meningitis, which is most often fatal when left untreated. [5] [29] Cryptococcal meningitis causes more than 180,000 deaths annually. [30] CNS (central nervous system) infections may also be present as a brain abscesses known as cryptococcomas, subdural effusions, dementia, isolated cranial nerve lesions, spinal cord lesions, and ischemic stroke. The estimated one-year mortality of HIV-related people who receive treatment for cryptococcal meningitis is 70% in low-income countries versus 20–30% for high-income countries. [31] Symptoms include headache, fever, neck stiffness, nausea and vomiting, photophobia. Diagnosis methods include a serum cryptococcal antigen test and lumbar puncture with cerebrospinal fluid (CSF) examination to detect C. neoformans. [32]

Treatment

C. neoformans seen in the lung of a patient with AIDS. Mucicarmine stain is used in this case, staining the inner capsule of the organism red. Cryptococcosis of lung in patient with AIDS. Mucicarmine stain 962 lores.jpg
C. neoformans seen in the lung of a patient with AIDS. Mucicarmine stain is used in this case, staining the inner capsule of the organism red.

Cryptococcosis that does not affect the central nervous system can be treated with fluconazole alone.

It was recommended in 2000 that cryptococcal meningitis be treated for two weeks with intravenous amphotericin B 0.7–1.0 mg/kg per day and oral flucytosine 100 mg/kg per day (or intravenous flucytosine 75 mg/kg per day[ citation needed ]day if the patient is unable to swallow), followed by oral fluconazole 400–800 mg daily for ten weeks [3] and then 200 mg daily for at least one year and until the patient's CD4 count is above 200 cells/mcl. [33] [34] Flucytosine is a generic, off-patent medicine, but the cost of two weeks of flucytosine therapy is about US$10,000,[ citation needed ] so that flucytosine has been unavailable in low- and middle-income countries. In 1970, flucytosine was available in Africa. [35] A dose of 200 mg/kg per day of flucytosine is associated with more side effects but is not more effective.[ citation needed ]

A single high dose of liposomal amphotericin B with 14 days of flucytosine and fluconazole is recommended by the newest WHO guideline for cryptococcal meningitis. [36] A new study found that brain glucose can trigger amphotericin B (AmB) tolerance of C. neoformans during meningitis which means it needs longer treatment time to kill the fungal cells. The study found that the brain glucose induced AmB tolerance of C. neoformans via glucose repression activator Mig1. Mig1 inhibits the production of ergosterol, the target of AmB, and promotes the production of inositol phosphoryl ceramide (IPC), which competes with AmB for ergosterol to limit AmB efficacy in mouse brain and human CSF. Strikingly, Results of this study indicated that IPC synthase inhibitor aureobasidin A (AbA) can enhance the anti-cryptococcal activity of AmB. AbA+AmB AmB had an even better therapeutic effect in a mouse model of cryptococcal meningitis than AmB+flucytosine which may bring new hope for the treatment of Cryptococcal meningitis. [30]

In Africa, oral fluconazole at a rate of 200 mg daily is often used. However, this does not result in cure, because it merely suppresses the fungus and does not kill it; viable fungus can continue to be grown from cerebrospinal fluid of patients not having taken fluconazole for many months. An increased dose of 400 mg daily does not improve outcomes, [37] but prospective studies from Uganda and Malawi reported that higher doses of 1200 mg per day have more fungicidal activity. [38] The outcomes with fluconazole monotherapy have 30% worse survival than amphotericin-based therapies, in a recent systematic review. [39]

The current treatment options for cryptococcosis are not optimal for treatment. [3] AmB is highly toxic to humans, and both fluconazole and flucytosine have been shown to cause development of drug resistanse in C. neoformans. A recent study from 2024 suggested brilacidin as an alternative treatment option. [34] Brilacidin was shown to be non-toxic and it caused no drug resistance development in C. neoformans, while still being efficient at causing fungal mortality. Brilacidin enhances permiability of the cell wall and membrane by binding to ergosterol and disrupting its distribution. It also affects the cell wall integrity pathway and disrupts calsium metabolism. Through these methods it not only causes cell mortality on its own, but also enables more effective use of other antifungal agents such as AmB against C. neoformans.

Related Research Articles

<i>Cryptococcus</i> Genus of fungi

Cryptococcus is a genus of fungi in the family Cryptococcaceae that includes both yeasts and filamentous species. The filamentous, sexual forms or teleomorphs were formerly classified in the genus Filobasidiella, while Cryptococcus was reserved for the yeasts. Most yeast species formerly referred to Cryptococcus have now been placed in different genera. The name Cryptococcus comes from the Greek for "hidden sphere". Some Cryptococcus species cause a disease called cryptococcosis.

<span class="mw-page-title-main">Amphotericin B</span> Antifungal and antiparasitaric chemical compound

Amphotericin B is an antifungal medication used for serious fungal infections and leishmaniasis. The fungal infections it is used to treat include mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis. For certain infections it is given with flucytosine. It is typically given intravenously.

<span class="mw-page-title-main">Cryptococcosis</span> Potentially fatal fungal disease

Cryptococcosis is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and in the brain, where it appears as a meningitis. Coughing, difficulty breathing, chest pain and fever are seen when the lungs are infected. When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity and confusion or changes in behavior. It can also affect other parts of the body including skin, where it may appear as several fluid-filled nodules with dead tissue.

<span class="mw-page-title-main">Fluconazole</span> Antifungal medication

Fluconazole is an antifungal medication used for a number of fungal infections. This includes candidiasis, blastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, dermatophytosis, and tinea versicolor. It is also used to prevent candidiasis in those who are at high risk such as following organ transplantation, low birth weight babies, and those with low blood neutrophil counts. It is given either by mouth or by injection into a vein.

<span class="mw-page-title-main">Opportunistic infection</span> Infection caused by pathogens that take advantage of an opportunity not normally available

An opportunistic infection is an infection caused by pathogens that take advantage of an opportunity not normally available. These opportunities can stem from a variety of sources, such as a weakened immune system, an altered microbiome, or breached integumentary barriers. Many of these pathogens do not necessarily cause disease in a healthy host that has a non-compromised immune system, and can, in some cases, act as commensals until the balance of the immune system is disrupted. Opportunistic infections can also be attributed to pathogens which cause mild illness in healthy individuals but lead to more serious illness when given the opportunity to take advantage of an immunocompromised host.

Intracellular parasites are microparasites that are capable of growing and reproducing inside the cells of a host. They are also called intracellular pathogens.

<span class="mw-page-title-main">Sporotrichosis</span> Medical condition

Sporotrichosis, also known as rose handler's disease, is a fungal infection that may be localised to skin, lungs, bone and joint, or become systemic. It presents with firm painless nodules that later ulcerate. Following initial exposure to Sporothrix schenckii, the disease typically progresses over a period of a week to several months. Serious complications may develop in people who have a weakened immune system.

<span class="mw-page-title-main">Flucytosine</span> Chemical compound

Flucytosine, also known as 5-fluorocytosine (5-FC), is an antifungal medication. It is specifically used, together with amphotericin B, for serious Candida infections and cryptococcosis. It may be used by itself or with other antifungals for chromomycosis. Flucytosine is used by mouth and by injection into a vein.

Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

<i>Nakaseomyces glabratus</i> Species of fungus

Nakaseomyces glabratus is a species of haploid yeast of the genus Nakaseomyces, previously known as Candida glabrata. Despite the fact that no sexual life cycle has been documented for this species, N. glabratus strains of both mating types are commonly found. N. glabrata is generally a commensal of human mucosal tissues, but in today's era of wider human immunodeficiency from various causes, N. glabratus is often the second or third most common cause of candidiasis as an opportunistic pathogen. Infections caused by N. glabratus can affect the urogenital tract or even cause systemic infections by entrance of the fungal cells in the bloodstream (Candidemia), especially prevalent in immunocompromised patients.

<i>Cryptococcus gattii</i> Species of fungus

Cryptococcus gattii, formerly known as Cryptococcus neoformans var. gattii, is an encapsulated yeast found primarily in tropical and subtropical climates. Its teleomorph is Filobasidiella bacillispora, a filamentous fungus belonging to the class Tremellomycetes.

Pathogenic fungi are fungi that cause disease in humans or other organisms. Although fungi are eukaryotic, many pathogenic fungi are microorganisms. Approximately 300 fungi are known to be pathogenic to humans; their study is called "medical mycology". Fungal infections are estimated to kill more people than either tuberculosis or malaria—about two million people per year.

<span class="mw-page-title-main">Fungal meningitis</span> Meningitis caused by a fungal infection

Fungal meningitis refers to meningitis caused by a fungal infection.

<span class="mw-page-title-main">OSU-03012</span> Chemical compound

OSU-03012 (AR-12) is a celecoxib derivative with anticancer and anti-microbial activity. Unlike celecoxib, OSU-03012 does not inhibit COX, but inhibits several other important enzymes instead which may be useful in the treatment of some forms of cancer, When combined with PDE5 inhibitors such as sildenafil or tadalafil, OSU-03012 was found to show enhanced anti-tumour effects in cell culture.

Vomocytosis is the cellular process by phagocytes expel live organisms that they have engulfed without destroying the organism. Vomocytosis is one of many methods used by cells to expel internal materials into their external environment, yet it is distinct in that both the engulfed organism and host cell remain undamaged by expulsion. As engulfed organisms are released without being destroyed, vomocytosis has been hypothesized to be utilized by pathogens as an escape mechanism from the immune system. The exact mechanisms, as well as the repertoire of cells that utilize this mechanism, are currently unknown, yet interest in this unique cellular process is driving continued research with the hopes of elucidating these unknowns.

<span class="mw-page-title-main">Arturo Casadevall</span> Cuban-American scientist

Arturo Casadevall is a Bloomberg Distinguished Professor of Molecular Microbiology & Immunology and Infectious Diseases at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, and the Alfred and Jill Sommer Professor and Chair of the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. He is an internationally recognized expert in infectious disease research, with a focus on fungal and bacterial pathogenesis and basic immunology of antibody structure-function. He was elected a member of the National Academy of Sciences in 2022.

<i>Trichosporon asteroides</i> Fungus of the genus Trichosporon

Trichosporon asteroides is an asexual basidiomycetous fungus first described from human skin but now mainly isolated from blood and urine. T. asteroides is a hyphal fungus with a characteristically yeast-like appearance due to the presence of slimy arthroconidia. Infections by this species usually respond to treatment with azoles and amphotericin B.

<span class="mw-page-title-main">Joseph Heitman</span>

Joseph Heitman is an American physician-scientist focused on research in genetics, microbiology, and infectious diseases. He is the James B. Duke Professor and Chair of the Department of Molecular Genetics and Microbiology at Duke University School of Medicine.

Naganishia albida is a species of fungus in the family Filobasidiaceae. It is currently only known from its yeast state. The species was originally isolated from the air in Japan, and has subsequently been isolated from dry moss in Portugal, grasshoppers in Portugal, and tubercular lungs.

<span class="mw-page-title-main">Chronic meningitis</span> Inflammation of the membranes surrounding the brain and spinal cord lasting longer than 4 weeks

Chronic meningitis is a long-lasting inflammation of the membranes lining the brain and spinal cord. By definition, the duration of signs, symptoms and inflammation in chronic meningitis last longer than 4 weeks. Infectious causes are a leading cause and the infectious organisms responsible for chronic meningitis are different than the organisms that cause acute infectious meningitis. Tuberculosis and the fungi cryptococcus are leading causes worldwide. Chronic meningitis due to infectious causes are more common in those who are immunosuppressed, including those with HIV infection or in children who are malnourished. Chronic meningitis sometimes has a more insidious course than acute meningitis. Also, some of the infectious agents that cause chronic infectious meningitis such as mycobacterium tuberculosis, many fungal species and viruses are difficult to isolate from the cerebrospinal fluid making diagnosis challenging. No cause is identified during initial evaluation in one third of cases. Magnetic resonance imaging (MRI) of the brain is more sensitive than computed tomography and may show radiological signs that suggest chronic meningitis, however no radiological signs are considered pathognomonic or characteristic. MRI is also normal in many cases further limiting its diagnostic utility.

References

  1. 1 2 3 Buchanan, Kent; Murphy, J. W. (1998). "What makes Cryptococcus neoformans a pathogen?". Emerging Infectious Diseases. 4 (1): 71–83. doi:10.3201/eid0401.980109. PMC   2627665 . PMID   9452400.
  2. ↑ Ingavale, Susham S.; Chang, Yun C.; Lee, Hyeseung; McClelland, Carol M.; Leong, Madeline L.; Kwon-Chung, Kgung J. (2008-09-01). "Importance of mitochondria in survival of Cryptococcus neoformans under low oxygen conditions and tolerance to Cobalt Chloride". PLOS Pathogens. 4 (9): e1000155. doi: 10.1371/journal.ppat.1000155 . ISSN   1553-7366. PMC   2528940 . PMID   18802457.
  3. 1 2 3 4 Melhem, Marcia; Júnior, Diniz; Takahashi, Juliana; Macioni, Milena; Oliveira, Lidiane; Siufi de Araújo, Lisandra; Fava, Wellington; Bonfietti, Lucas; Paniago, Anamaria; Venturini, James; Espinel-Ingroff, Ana (29 January 2024). "Antifungal Resistance in Cryptococcal Infections". Pathogens. 13 (2): 128. doi: 10.3390/pathogens13020128 . PMC   10891860 . PMID   38392866.
  4. ↑ Bahn, Yong-Sun; Sun, Sheng; Heitman, Joseph; Lin, Xiaorong (2020-09-01). "Microbe Profile: Cryptococcus neoformans species complex". Microbiology. 166 (9): 797–799. doi: 10.1099/mic.0.000973 . ISSN   1350-0872. PMC   7717486 . PMID   32956032.
  5. 1 2 3 4 Coussement, Julien; Heath, Christopher; Roberts, Matthew; Lane, Rebekah; Spelman, Tim; Smibert, Olivia; Longhitano, Anthony; Morrisey, Orla; Nield, Blake; Tripathy, Monica; Davis, Joshua; Kennedy, Karina; Lynar, Sarah; Crawford, Lucy; Slavin, Monica (26 May 2023). "Current Epidemiology and Clinical Features of Cryptococcus Infection in Patients Without Human Immunodeficiency Virus: A Multicenter Study in 46 Hospitals in Australia and New Zealand". Clinical Infectious Diseases. 77 (7): 976–986. doi:10.1093/cid/ciad321. PMID   37235212.
  6. ↑ Hagen, Ferry; Khayhan, Kantarawee; Theelen, Bart; Kolecka, Anna; Polacheck, Itzhack; Sionov, Edward; Falk, Rama; Parnmen, Sittiporn; Lumbsch, H. Thorsten (2015-05-01). "Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex". Fungal Genetics and Biology. 78: 16–48. doi: 10.1016/j.fgb.2015.02.009 . ISSN   1096-0937. PMID   25721988.
  7. ↑ Kwon-Chung KJ. (1975). "A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans". Mycologia. 67 (6): 1197–1200. doi:10.2307/3758842. JSTOR   3758842. PMID   765816.
  8. ↑ Heitman, Joseph; Kozel, Thomas R.; Kwon-Chung, Kyung J.; Perfect, John R.; Casadevall, Arturo, eds. (2011). Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press. doi:10.1128/9781555816858. ISBN   9781683671220.
  9. ↑ Bottone, E J (1980). "Cryptococcus neoformans: pitfalls in diagnosis through evaluation of gram-stained smears of purulent exudates". Journal of Clinical Microbiology. 12 (6): 790–1. doi:10.1128/jcm.12.6.790-791.1980. PMC   273699 . PMID   6171578.
  10. ↑ Zerpa, R; Huicho, L; Guillén, A (September 1996). "Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens". Journal of Clinical Microbiology. 34 (9): 2290–1. doi:10.1128/JCM.34.9.2290-2291.1996. PMC   229234 . PMID   8862601.
  11. ↑ Shashikala; Kanungo, R; Srinivasan, S; Mathew, R; Kannan, M (Jul–Sep 2004). "Unusual morphological forms of Cryptococcus neoformans in cerebrospinal fluid". Indian Journal of Medical Microbiology. 22 (3): 188–90. doi: 10.1016/S0255-0857(21)02835-8 . PMID   17642731.
  12. ↑ Antinori, Spinello; Radice, Anna; Galimberti, Laura; Magni, Carlo; Fasan, Marco; Parravicini, Carlo (November 2005). "The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis" (PDF). Journal of Clinical Microbiology. 43 (11): 5828–9. doi:10.1128/JCM.43.11.5828-5829.2005. PMC   1287839 . PMID   16272534.
  13. ↑ Dadachova E; et al. (2007). Rutherford, Julian (ed.). "Ionizing Radiation Changes the Electronic Properties of Melanin and Enhances the Growth of Melanized Fungi". PLOS ONE. 2 (5): e457. Bibcode:2007PLoSO...2..457D. doi: 10.1371/journal.pone.0000457 . PMC   1866175 . PMID   17520016.
  14. ↑ Tripathi, K; Mor, V; Bairwa, NK; Del Poeta, M; Mohanty, BK (2012). "Hydroxyurea treatment inhibits proliferation of Cryptococcus neoformans in mice". Front Microbiol. 3: 187. doi: 10.3389/fmicb.2012.00187 . PMC   3390589 . PMID   22783238.
  15. ↑ Alvarez, M.; Burns, T.; Luo, Y.; Pirofski, L. A.; Casadevall, A. (2009). "The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes". BMC Microbiology. 9: 51. doi: 10.1186/1471-2180-9-51 . PMC   2670303 . PMID   19265539.
  16. ↑ Charlier, C; Nielsen, K; Daou, S; Brigitte, M; Chretien, F; Dromer, F (January 2009). "Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans". Infection and Immunity. 77 (1): 120–7. CiteSeerX   10.1.1.336.3329 . doi:10.1128/iai.01065-08. PMC   2612285 . PMID   18936186.
  17. ↑ Sabiiti, W; Robertson, E; Beale, MA; Johnston, SA; Brouwer, AE; Loyse, A; Jarvis, JN; Gilbert, AS; Fisher, MC; Harrison, TS; May, RC; Bicanic, T (May 2014). "Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis". The Journal of Clinical Investigation. 124 (5): 2000–8. doi:10.1172/jci72950. PMC   4001551 . PMID   24743149.
  18. ↑ Alvarez, M; Casadevall, A (7 November 2006). "Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages". Current Biology. 16 (21): 2161–5. Bibcode:2006CBio...16.2161A. doi: 10.1016/j.cub.2006.09.061 . PMID   17084702. S2CID   1612240.
  19. ↑ Ma, H; Croudace, JE; Lammas, DA; May, RC (7 November 2006). "Expulsion of live pathogenic yeast by macrophages". Current Biology. 16 (21): 2156–60. Bibcode:2006CBio...16.2156M. doi: 10.1016/j.cub.2006.09.032 . PMID   17084701. S2CID   11639313.
  20. ↑ Casadevall, A (2012). "Amoeba Provide Insight into the Origin of Virulence in Pathogenic Fungi". Recent Advances on Model Hosts. Advances in Experimental Medicine and Biology. Vol. 710. pp. 1–10. doi:10.1007/978-1-4419-5638-5_1. ISBN   978-1-4419-5637-8. PMID   22127880.
  21. ↑ Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J (2009). "Spores as infectious propagules of Cryptococcus neoformans". Infect Immun. 77 (10): 4345–55. doi:10.1128/IAI.00542-09. PMC   2747963 . PMID   19620339.
  22. 1 2 3 Fan W, Kraus PR, Boily MJ, Heitman J (2005). "Cryptococcus neoformans gene expression during murine macrophage infection". Eukaryot Cell. 4 (8): 1420–1433. CiteSeerX   10.1.1.333.7376 . doi:10.1128/EC.4.8.1420-1433.2005. PMC   1214536 . PMID   16087747.
  23. ↑ Alspaugh JA, Granger DL (1991). "Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis". Infect Immun. 59 (7): 2291–2296. doi:10.1128/IAI.59.7.2291-2296.1991. PMC   258009 . PMID   2050398.
  24. ↑ Liu TB (2012). "Molecular mechanisms of cryptococcal meningitis". Virulence. 3 (2): 173–81. doi:10.4161/viru.18685. PMC   3396696 . PMID   22460646.
  25. ↑ Xu CY (Feb 2014). "permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitis". J Int Med Res. 42 (1): 85–92. doi: 10.1177/0300060513504365 . PMID   24398759.
  26. ↑ "Fungal protein found to cross blood-brain barrier". University of California at Davis. 12 June 2014 – via MedicalXpress.
  27. 1 2 Lin X, Hull CM, Heitman J (2005). "Sexual reproduction between partners of the same mating type in Cryptococcus neoformans". Nature. 434 (7036): 1017–1021. Bibcode:2005Natur.434.1017L. doi:10.1038/nature03448. PMID   15846346. S2CID   52857557.
  28. ↑ Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens". Infect Genet Evol. 8 (3): 267–285. Bibcode:2008InfGE...8..267M. doi:10.1016/j.meegid.2008.01.002. PMID   18295550.
  29. ↑ Bicanic, Tihana; Harrison, Thomas S. (1 January 2004). "Cryptococcal meningitis". British Medical Bulletin. 72 (1): 99–118. doi:10.1093/bmb/ldh043. ISSN   1471-8391. PMID   15838017.
  30. 1 2 Chen, Lei; Tian, Xiuyun; Zhang, Lanyue; Wang, Wenzhao; Hu, Pengjie; et al. (15 January 2024). "Brain glucose induces tolerance of Cryptococcus neoformans to amphotericin B during meningitis". Nature Microbiology. 9 (2): 346–358. doi:10.1038/s41564-023-01561-1. ISSN   2058-5276. PMID   38225460.
  31. ↑ Rajasingham, Radha; Smith, Rachel M; Park, Benjamin J; Jarvis, Joseph N; Govender, Nelesh P; et al. (2017). "Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis". The Lancet Infectious Diseases. 17 (8): 873–881. doi:10.1016/S1473-3099(17)30243-8. PMC   5818156 . PMID   28483415.
  32. ↑ Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization (WHO). 27 June 2022. ISBN   978-92-4-005217-8.
  33. ↑ Martínez E, García-Viejo MA, Marcos MA, et al. (2000). "Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy". AIDS. 14 (16): 2615–26. doi: 10.1097/00002030-200011100-00029 . PMID   11101078.
  34. 1 2 Diehl, Camila; Pinzan, Camila; Alves de Castro, Patrícia; Delbaje, Endrews; García Carnero, Laura; Sánchez-León, Eddy; Bhalla, Kabir; Kronstad, James; Kim, Dong-gyu; Doering, Tamara; Alkhazraji, Sondus; Misha, Nagendra; Idrahin, Ashraf; Yoshimura, Mami; Goldman, Gustavo (25 June 2024). "Brilacidin, a novel antifungal agent against Cryptococcus neoformans". mBio. 15 (2): e01031-24. doi:10.1128/mbio.01031-24. PMID   38916308 – via ASM Journals.
  35. ↑ Mpairwe Y, Patel KM (1970). "Cryptococcal meningitis in Mulago Hospital, Kampala". East Afr Med J. 47 (8): 445–7. PMID   5479794.
  36. ↑ "New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV".
  37. ↑ CF Schaars; Meintjes GA; Morroni C; et al. (2006). "Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole". BMC Infect Dis. 6: 118. doi: 10.1186/1471-2334-6-118 . hdl:11427/14193. PMC   1540428 . PMID   16846523.
  38. ↑ Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, Wall E, Andia I, Jaffar S, Harrison TS (2008). "Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda". Clin Infect Dis. 47 (12): 1556–61. doi: 10.1086/593194 . PMID   18990067.
  39. ↑ Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR (2012). "Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis". PLOS Med. 9 (9): e1001316. doi: 10.1371/journal.pmed.1001316 . PMC   3463510 . PMID   23055838.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.